Improvement of Remission Duration with Low-Dose Post-Remissional Gemtuzumab Ozogamicin (GO) in Elderly Patients with Acute Myeloid Leukemia

Filippo Marmont(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Umberto Vitolo(Candiolo Cancer Institute), Stefano D’Ardìa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Flavia Salvi(Azienda Sanitaria Locale Alessandria), Anna Tonso, Alessandro Levis(San Antonio College), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Dario Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Blood
November 16, 2008
10.1182/blood.v112.11.4024.4024
Cited by 0

Related Papers

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage
|Blood|2008|253
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP
|Blood|2012|238
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|228
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
|Annals of Oncology|2012|218